Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leflunomide and methotrexate.

R F Laan1, P L van Riel, L B van de Putte

  • 1University Medical Center Nijmegen, Department of Rheumatology, Nijmegen, The Netherlands. R.Laan@reuma.azn.nl

Current Opinion in Rheumatology
|May 3, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA?

Clinical and experimental rheumatology·2002
Same author

Role of activatory Fc gamma RI and Fc gamma RIII and inhibitory Fc gamma RII in inflammation and cartilage destruction during experimental antigen-induced arthritis.

The American journal of pathology·2001
Same author

The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

Arthritis and rheumatism·2001
Same author

[Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].

Nederlands tijdschrift voor geneeskunde·2001
Same author

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine.

Annals of the rheumatic diseases·2001
Same author

Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement.

Annals of the rheumatic diseases·2001
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Leflunomide is a new drug for rheumatoid arthritis, showing similar effectiveness to methotrexate and sulfasalazine. It works by interfering with pyrimidine synthesis.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) management involves disease-modifying antirheumatic drugs (DMARDs).
  • Methotrexate (MTX) is a long-established RA treatment.
  • Leflunomide (LEF) is a newer DMARD with emerging clinical data.

Purpose of the Study:

  • To compare the efficacy and safety of leflunomide with methotrexate and sulfasalazine in rheumatoid arthritis patients.
  • To elucidate the mechanism of action of leflunomide.

Main Methods:

  • Review of recent large clinical trials comparing leflunomide to methotrexate, sulfasalazine, and placebo.
  • Analysis of pharmacological data regarding leflunomide's mechanism of action.

Main Results:

Related Experiment Videos

  • Leflunomide demonstrates comparable efficacy to methotrexate and sulfasalazine in treating rheumatoid arthritis.
  • Emerging data suggest leflunomide acts as an immunomodulatory agent.
  • Its mechanism involves interference with de novo pyrimidine synthesis.

Conclusions:

  • Leflunomide is an effective treatment option for rheumatoid arthritis, comparable to established therapies.
  • Understanding leflunomide's immunomodulatory effects, particularly its impact on pyrimidine synthesis, is crucial for its clinical application.